| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg | |||
| Other Sizes |
| Targets |
Target: alpha7 nAChR (alpha7 nicotinic acetylcholine receptor, JAK2, STAT3). This compound acts as an agonist of the alpha7 nAChR, which is expressed on immune cells and mediates the cholinergic anti-inflammatory reflex. Activation of alpha7 nAChR leads to JAK2/STAT3 signaling pathway activation, which suppresses NF-kappaB activation and reduces the production of pro-inflammatory mediators (NO, TNF-alpha, IL-1beta, IL-6).
|
|---|---|
| ln Vitro |
In vitro, alpha7 nAChR-JAK2-STAT3 agonist 1 inhibits NO production with an IC50 of 0.32 uM in LPS-stimulated RAW264.7 mouse macrophages. It effectively suppresses LPS-induced iNOS (inducible nitric oxide synthase), IL-1beta, and IL-6 expression. It also inhibits LPS-induced NF-kappaB activation, cytokine production, and NO release in a concentration-dependent manner. No cytotoxicity is reported at effective concentrations.
|
| ln Vivo |
No in vivo efficacy data have been published specifically for this compound in animal models. However, based on its mechanism of action (activation of alpha7 nAChR-JAK2-STAT3 pathway and suppression of pro-inflammatory cytokines), it has potential for treating sepsis and other inflammatory diseases. Animal studies are expected to include LPS-induced septic shock models in mice or cecal ligation and puncture (CLP) models of sepsis.
|
| Enzyme Assay |
For cell-free assays: Not directly applicable for this pathway modulator, as the alpha7 nAChR is a membrane receptor. For cell-free JAK2/STAT3 activation assays, cell lysates from treated cells can be analyzed by Western blot for phosphorylated JAK2 (p-JAK2), phosphorylated STAT3 (p-STAT3), and total protein levels. For NO measurement, cell culture supernatants are collected and mixed with Griess reagent (1% sulfanilamide, 0.1% N-(1-naphthyl)ethylenediamine dihydrochloride in 2.5% phosphoric acid), and absorbance is read at 540 nm. IC50 (0.32 uM) is calculated from dose-response curves.
|
| Cell Assay |
For cell-based assays: RAW264.7 mouse macrophages are seeded in 96-well plates (1×10^5 cells/well) in DMEM medium. Cells are pretreated with alpha7 nAChR-JAK2-STAT3 agonist 1 (0.01-10 uM) for 30-60 min, then stimulated with LPS (1 ug/mL) for 16-24 h at 37degC. Supernatants are collected for NO measurement by Griess reagent. Cells are lysed for iNOS, IL-1beta, IL-6, and beta-actin Western blot. NF-kappaB activation is assessed by measuring p65 nuclear translocation by immunofluorescence or by measuring p-IkappaBalpha levels by Western blot.
|
| Animal Protocol |
For in vivo animal studies: potential protocol involves LPS-induced septic shock model in mice. Male C57BL/6J mice are administered alpha7 nAChR-JAK2-STAT3 agonist 1 intraperitoneally (1-10 mg/kg) 30 min before LPS challenge (10 mg/kg, IP). Blood is collected 2-6 h post-LPS for cytokine (TNF-alpha, IL-1beta, IL-6, IL-10) measurement by ELISA. Lung and liver tissues are harvested for MPO activity and histopathological analysis. Survival is monitored over 24-48 h. No published data available for this specific compound.
|
| ADME/Pharmacokinetics |
PK properties of alpha7 nAChR-JAK2-STAT3 agonist 1: For a small molecule agonist (MW 426.5, solubility in DMSO 100 mg/mL), predicted PK in rodents after IP administration: moderate bioavailability, Tmax 0.5-1 h, plasma half-life 2-4 h. The compound likely penetrates the blood-brain barrier, as alpha7 nAChR agonists generally have CNS activity. Metabolism is likely via CYP450-mediated oxidation. No formal PK studies have been published.
|
| Toxicity/Toxicokinetics |
No toxicity data have been reported for this compound. Based on its mechanism, activation of the alpha7 nAChR-JAK2-STAT3 pathway is generally associated with anti-inflammatory effects, and alpha7 nAChR agonists have shown good safety profiles in clinical trials for inflammatory diseases. However, overactivation of JAK2-STAT3 may have potential risks (e.g., immunosuppression, off-target effects). No acute toxicity or LD50 studies have been published. The compound is for research use only.
|
| References | |
| Additional Infomation |
alpha7 nAChR-JAK2-STAT3 agonist 1 is a research compound not yet approved for clinical use. It is a valuable chemical probe for studying the cholinergic anti-inflammatory pathway and the role of alpha7 nAChR signaling in sepsis, inflammation, and immunity. It has potential applications in treating sepsis, acute respiratory distress syndrome (ARDS), inflammatory bowel disease (IBD), rheumatoid arthritis, and other inflammatory disorders. It may also have potential in neurodegenerative diseases where alpha7 nAChR plays a role (Alzheimer's disease, Parkinson's disease).
|
| Molecular Formula |
C25H30O6
|
|---|---|
| Molecular Weight |
426.502108097076
|
| Exact Mass |
426.204
|
| CAS # |
2108714-20-9
|
| PubChem CID |
163408847
|
| Appearance |
Colorless to light yellow liquid
|
| LogP |
5.2
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
14
|
| Heavy Atom Count |
31
|
| Complexity |
568
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CC(=O)OC1=C(C=C(C=C1)CC[C@H](CCCCC2=CC=CC=C2)OC(=O)C)OC(=O)C
|
| InChi Key |
ONTKJJHFOWPHNJ-QHCPKHFHSA-N
|
| InChi Code |
InChI=1S/C25H30O6/c1-18(26)29-23(12-8-7-11-21-9-5-4-6-10-21)15-13-22-14-16-24(30-19(2)27)25(17-22)31-20(3)28/h4-6,9-10,14,16-17,23H,7-8,11-13,15H2,1-3H3/t23-/m0/s1
|
| Chemical Name |
[2-acetyloxy-4-[(3S)-3-acetyloxy-7-phenylheptyl]phenyl] acetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3447 mL | 11.7233 mL | 23.4467 mL | |
| 5 mM | 0.4689 mL | 2.3447 mL | 4.6893 mL | |
| 10 mM | 0.2345 mL | 1.1723 mL | 2.3447 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
